|
1
|
Rawson TM, Moore LS, Castro-Sanchez E,
Charani E, Davies F, Satta G, Ellington MJ and Holmes AH: COVID-19
and the potential long-term impact on antimicrobial resistance. J
Antimicrob Chemother. 75:1681–1684. 2020.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huttner BD, Catho G, Pano-Pardo JR,
Pulcini C and Schouten J: COVID-19: don't neglect antimicrobial
stewardship principles! Clin Microbiol. Infect. 26:808–810.
2020.PubMed/NCBI View Article : Google Scholar
|
|
3
|
McCullers JA: The co-pathogenesis of
influenza viruses with bacteria in the lung. Nat Rev Microbiol.
12:252–262. 2014.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Mirzaei R, Goodarzi P, Asadi M, Soltani A,
Aljanabi HAA, Jeda AS, Dashtbin S, Jalalifar S, Mohammadzadeh R,
Teimoori A, et al: Bacterial co-infections with SARS-CoV-2. IUBMB
Life. 72:2097–2111. 2020.PubMed/NCBI View
Article : Google Scholar
|
|
5
|
Zhang G, Hu C, Luo L, Fang F, Chen Y, Li
J, Peng Z and Pan H: Clinical features and short-term outcomes of
221 patients with COVID-19 in Wuhan, China. J Clin Virol.
127(104364)2020.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Mazzariol A, Benini A, Unali I, Nocini R,
Smania M, Bertoncelli A, De Sanctis F, Ugel S, Donadello K, Polati
E and Gibellini D: Dynamics of SARS-CoV2 infection and multi-drug
resistant bacteria superinfection in patients with assisted
mechanical ventilation. Front Cell Infect Microbiol.
11(683409)2021.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Garcia-Vidal C, Sanjuan G, Moreno-García
E, Puerta-Alcalde P, Garcia-Pouton N, Chumbita M, Fernandez-Pittol
M, Pitart C, Inciarte A, Bodro M, et al: Incidence of co-infections
and superinfections in hospitalized patients with COVID-19: A
retrospective cohort study. Clin Microbiol Infect. 27:83–88.
2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Bengoechea JA and Bamford CG: SARS-CoV-2,
bacterial co-infections, and AMR: the deadly trio in COVID-19? EMBO
Mol Med. 12(e12560)2020.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Baskaran V, Lawrence H, Lansbury LE, Webb
K, Safavi S, Zainuddin NI, Huq T, Eggleston C, Ellis J, Thakker C,
et al: Co-infection in critically ill patients with COVID-19: An
observational cohort study from England. J Med Microbiol.
70(001350)2021.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Kim JH, Seo JW, Mok JH, Kim MH, Cho WH,
Lee K, Kim KU, Jeon D, Park HK, Kim YS, et al: Usefulness of plasma
procalcitonin to predict severity in elderly patients with
community-acquired pneumonia. Tuberc Respir Dis (Seoul).
74:207–214. 2013.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Lippi G and Plebani M: Procalcitonin in
patients with severe coronavirus disease 2019 (COVID-19): A
meta-analysis. Clin Chim Acta. 505:190–191. 2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Wolfisberg S, Gregoriano C and Schuetz P:
Procalcitonin for individualizing antibiotic treatment: An update
with a focus on COVID-19. Crit Rev Clin Lab Sci. 59:54–65.
2022.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Metersky ML, Masterton RG, Lode H, File TM
Jr and Babinchak T: Epidemiology, microbiology, and treatment
considerations for bacterial pneumonia complicating influenza. Int
J Infect Dis. 16:e321–e331. 2012.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Anton-Vazquez V and Clivillé R:
Streptococcus pneumoniae coinfection in hospitalised patients with
COVID-19. Eur J Clin Microbiol Infect Dis. 40:1353–1355.
2021.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Lansbury L, Lim B, Baskaran V and Lim WS:
Co-infections in people with COVID-19: A systematic review and
meta-analysis. J Infect. 81:266–275. 2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Rawson TM, Moore LS, Zhu N, Ranganathan N,
Skolimowska K, Gilchrist M, Satta G, Cooke G and Holmes A:
Bacterial and fungal coinfection in individuals with coronavirus: A
rapid review to support COVID-19 antimicrobial prescribing. Clin
Infect Dis. 71:2459–2468. 2020.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Bassetti M, Kollef MH and Timsit JF:
Bacterial and fungal superinfections in critically ill patients
with COVID-19. Intensive Care Med. 46:2071–2074. 2020.PubMed/NCBI View Article : Google Scholar
|
|
18
|
d'Humières C, Patrier J, Lortat-Jacob B,
Tran-Dinh A, Chemali L, Maataoui N, Rondinaud E, Ruppé E, Burdet C,
Ruckly S, et al: Two original observations concerning bacterial
infections in COVID-19 patients hospitalized in intensive care
units during the first wave of the epidemic in France. PLoS One.
16(e0250728)2021.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Adalbert JR, Varshney K, Tobin R and
Pajaro R: Clinical outcomes in patients co-infected with COVID-19
and Staphylococcus aureus: A scoping review. BMC Infect Dis.
21:1–7. 2021.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Falcone M, Tiseo G, Giordano C, Leonildi
A, Menichini M, Vecchione A, Pistello M, Guarracino F, Ghiadoni L,
Forfori F, et al: Predictors of hospital-acquired bacterial and
fungal superinfections in COVID-19: A prospective observational
study. J Antimicrob Chemother. 76:1078–1084. 2021.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Stegeman I, Ochodo EA, Guleid F, Holtman
GA, Yang B, Davenport C, Deeks JJ, Dinnes J, Dittrich S, Emperador
D, et al: Routine laboratory testing to determine if a patient has
COVID-19. Cochrane Database Syst Rev. 11(CD013787)2020.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Garrido P, Cueto P, Rovira C, Garcia E,
Parra A, Enriquez R, Pinos A, Sosa M, Hernández-Aguilera A and
Vallverdú I: Clinical value of procalcitonin in critically ill
patients infected by SARS-CoV-2. Am J Emerg Med. 46:525–531.
2021.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Hariyanto TI, Japar KV, Kwenandar F, Damay
V, Siregar JI, Lugito NP, Tjiang MM and Kurniawan A: Inflammatory
and hematologic markers as predictors of severe outcomes in
COVID-19 infection: A systematic review and meta-analysis. Am J
Emerg Med. 41:110–119. 2021.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Del Sole F, Farcomeni A, Loffredo L,
Carnevale R, Menichelli D, Vicario T, Pignatelli P and Pastori D:
Features of severe COVID-19: A systematic review and meta-analysis.
Eur J Clin Invest. 50(e13378)2020.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Müller B and Becker KL: Procalcitonin: How
a hormone became a marker and mediator of sepsis. Swiss Med Wkly.
131:595–602. 2001.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Huespe I, Prado E, Staneloni I, Contrera
N, Denaday L, San Roman E and Sinner J: Kinetics of procalcitonin
in infections caused by multidrug-resistant bacteria. Medicina (B
Aires). 80:599–605. 2020.PubMed/NCBI
|
|
27
|
Ponti G, Maccaferri M, Ruini C, Tomasi A
and Ozben T: Biomarkers associated with COVID-19 disease
progression. Crit Rev Clin Lab Sci. 57:389–399. 2020.PubMed/NCBI View Article : Google Scholar
|
